Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Uterine Serous Carcinoma: early-phase trial registry

2 of 5 indexed Uterine Serous Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Uterine Serous Carcinoma: 5 US clinical trials tracked, 2 recruiting.

Uterine Serous Carcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition uterine-serous-carcinoma

OPEN 2 | RECR 40% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1

Volume-matched condition peers

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Uterine Serous Carcinoma (th…40%
Open-enrollment share among volume-matched conditions near Uterine Serous Carcinoma

Uterine Serous Carcinoma lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Uterine Serous Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Uterine Serous Carcinoma is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Uterine Serous Carcinoma research.

    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Uterine Serous Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 92 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Uterine Serous Carcinoma research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 24

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4

Top Sponsors

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals 1 trials
Volastra Therapeutics 1 trials
Joyce Liu, MD 1 trials
Northwell Health 1 trials
AstraZeneca 1 trials

Named interventions

Most-linked intervention names on Uterine Serous Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Azenosertib Drug
2 trials
Adavosertib Drug
1 trials
VLS-1488 Drug
1 trials
Niraparib Drug
1 trials

US sites by state

Facility locations filed on Uterine Serous Carcinoma trials. A trial with sites in several states counts in each.

New York 3 trials
New Jersey 3 trials
California 3 trials
Michigan 2 trials
Maryland 2 trials
Massachusetts 2 trials
Illinois 2 trials
Colorado 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Uterine Serous Carcinoma page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Uterine Serous Carcinoma condition card totals 5 registered trials; most-linked intervention Azenosertib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.